Your browser doesn't support javascript.
loading
Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.
Zhang, Jikai; Hu, Zhongyu; He, Jianfeng; Liao, Yuyi; Li, Yuan; Pei, Rongjuan; Fang, Xin; Zeng, Peiyu; Fan, Renfeng; Ou, Zhiqiang; Deng, Jinglong; Zhou, Jian; Guan, Wuxiang; Min, Yuanqin; Deng, Fei; Peng, Hua; Zhang, Zheng; Feng, Chunyan; Xin, Baobao.
Afiliação
  • Zhang J; Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.
  • Hu Z; National Institutes for Food and Drug Control, Beijing, People's Republic of China.
  • He J; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, People's Republic of China.
  • Liao Y; Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.
  • Li Y; Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.
  • Pei R; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Fang X; National Institutes for Food and Drug Control, Beijing, People's Republic of China.
  • Zeng P; Gaozhou Center for Disease Control and Prevention, Maoming, People's Republic of China.
  • Fan R; Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.
  • Ou Z; Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, People's Republic of China.
  • Deng J; Gaozhou Center for Disease Control and Prevention, Maoming, People's Republic of China.
  • Zhou J; Gaozhou Center for Disease Control and Prevention, Maoming, People's Republic of China.
  • Guan W; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Min Y; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Deng F; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Peng H; Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, People's Republic of China.
  • Zhang Z; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
  • Feng C; LivzonBio Inc., Zhuhai, People's Republic of China.
  • Xin B; LivzonBio Inc., Zhuhai, People's Republic of China.
Emerg Microbes Infect ; 10(1): 1589-1597, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34197281
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferons / Imunogenicidade da Vacina / Vacinas contra COVID-19 / COVID-19 / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferons / Imunogenicidade da Vacina / Vacinas contra COVID-19 / COVID-19 / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article